Axellis Paves the Way to Becoming an International Leader in Oncology and Cardiology Technology

Axellis Ltd, the UK and US based medical technology company, has
signalled its intent to become a leading, global provider of
specialist hardware and software solutions to optimise treatments in
Oncology and Cardiology with the announcement of three significant
acquisitions.

The first three acquisitions completed by Axellis are part of the
company´s strategy to create a software solutions business with a full
suite of complimentary technologies that will support and add value to
today´s Oncology and Cardiology programmes. The acquisitions will also
enable Axellis to immediately access the buoyant US healthcare market
which launches the development of its ambitious business plan.

Commenting on the acquisitions and the growth potential of
Axellis, Trevor Stanley, CEO said: "In making these acquisitions,
Axellis has quickly and clearly established itself as an emerging
leader in the provision of advanced software tools to support the
oncology and cardiology sectors, as well as adding an exceptional team
of founder-managers. Not only do these businesses each have
significant growth potential in their own right, but they offer
tremendous synergies to rapidly grow our healthcare business through
the integration of the suite of proprietary software tools, patented
technologies and derived medical products now available from Axellis.
These systems will become the cornerstones of Axellis´ patient-centred
vision".

Acquisitions

Innocure LLC is a US-based specialist developer of Oncology
software tools and the manufacture of a new, advanced design of
compensating filters used in conjunction with linear accelerators for
the delivery of intensity modulated radiation therapy. Three of
Innocure´s proprietary compensators, received FDA 510K registration in
March 2006 and the company currently has approval for the
reimbursement of treatments utilising the devices from both Medicare
and Medicaid centres. Dr. Donald W. Collins, founder and CTO of
Innocure, will join the Axellis leadership team where he will
contribute his deep domain expertise and extensive knowledge of the US
Healthcare market.

Bluescope Medical Technologies Ltd is a leading developer of
non-invasive advanced cardio-pulmonary acoustic monitoring systems
used to measure cardiac and respiratory sounds, in addition to the
measurement and assessment of the electrical information generated by
the heart. The company´s latest devices under development are designed
to provide more accurate diagnosis and monitoring of patients in acute
critical care environments as well as in remote community settings.
Dr. Peter Donnelly and Andy O´Hara, who jointly built the Bluescope
technology platform, and their key staff have joined Axellis and will
continue to contribute comprehensive software engineering, technical
and business skills to lead innovation in the Cardiology and Oncology
markets.

Mailling Wright Products Ltd uses digital technology to capture
patient data, perform analysis in the remote design and off-site
manufacture of patient-specific immobilisation devices and appliances
for use in radiotherapy. Co-founders Michael Mailling and John Wright
join the Axellis leadership team where their broad understanding of 3D
data processing, derived design and manufacturing in the healthcare
sector will be invaluable as Axellis moves into its own production of
medical devices and ancillary support systems designed for individual
patients.

The Axellis website is currently under construction.